Bengisu Turgutalp

Dr. Bengisu Turgutalp

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BTBengisu Turgutalp
Bengisu Turgutalp
PBPrabesh Bhattarai
Prabesh Bhattarai
TETugba Ercetin
Tugba Ercetin
CLChiara Luise
Chiara Luise
RRRengin Reis
Rengin Reis
MYMine Yarim
Mine Yarim

11 September 2026 in Nature Aging
Verified
Journal Article
Open access
PDF file
PBPrabesh Bhattarai
Prabesh Bhattarai
EYElanur Yilmaz
Elanur Yilmaz
ECElif Öykü Cakir
Elif Öykü Cakir
HTHuseyin Tayran
Huseyin Tayran
IHImdadul Haq
Imdadul Haq
CKCaghan Kizil
Caghan Kizil
Blood–brain barrier (BBB) dysfunction is an early feature of Alzheimer’s disease (AD) and is particularly pronounced in individuals carrying the APOE ε4 allele, but the mechanisms linking APOE ε4 to BBB failure remain unclear. Here we show that astrocyte-derived fibronectin (FN1) is a key mediator of apolipoprotein E4 (APOE4)-driven BBB dysfunction in AD. Using postmortem human brain tissue, human three-dimensional vascular models and in vivo models, we demonstrate that APOE4, amyloid-β42 and inflammatory signals induce astrocytic FN1 upregulation and excessive perivascular deposition. Fibronectin accumulation is sufficient to cause BBB leakage and disrupt VEGF/HB-EGF/IGF-1 signaling through integrin-mediated focal adhesion kinase activity. Reducing fibronectin or restoring growth factor signaling rescues BBB function in vitro and in vivo. Together, evidence from experimental models, human brain tissue and clinical datasets identifies fibronectin as a proximal mediator of APOE4-driven gliovascular dysfunction and highlights FN1 as a potential therapeutic target for vascular and BBB dysfunction in AD.

26 June 2025 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
BVBalazs R. Varga
Balazs R. Varga
RURajendra Uprety
Rajendra Uprety
BPBarnali Paul
Barnali Paul
AKAlexis Knoll
Alexis Knoll
NRNokomis Ramos-Gonzalez
Nokomis Ramos-Gonzalez
SMSusruta Majumdar
Susruta Majumdar

20 September 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BTBengisu Turgutalp
Bengisu Turgutalp
MUMerve Uslu
Merve Uslu
SHSinem Helvacioglu
Sinem Helvacioglu
MCMohammad Charehsaz
Mohammad Charehsaz
EGEnise Ece Gurdal
Enise Ece Gurdal
MYMine Yarim
Mine Yarim

16 January 2018 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
EGEnise Ece Gurdal
Enise Ece Gurdal
BTBengisu Turgutalp
Bengisu Turgutalp
HGHayrettin Ozan Gulcan
Hayrettin Ozan Gulcan
TETugba Ercetin
Tugba Ercetin
MSMustafa Fethi Sahin
Mustafa Fethi Sahin
MYMine Yarim
Mine Yarim
Objective and Method: A new series of benzothiazole-piperazine derivatives was synthesized and a complete chemical characterization of the novel compounds was provided. In vitro cytotoxic activities were screened against colorectal (HCT-116), breast (MCF-7) and hepatocellular (Huh7) cancer cell lines by Sulforhodamine B assay. Result and Discussion: All compounds showed cytotoxic activity against hepatocellular (Huh7) and breast (MCF-7) cancer cell lines. Dihalo substituted benzylpiperazine derivatives (2a, 2e) had the highest cytotoxic activities in all the tested cell lines. In addition, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of synthesized compounds were investigated by in vitro Ellman's method. Compound 2j led to moderate and selective inhibition against AChE. Docking study was utilized to understand the binding mode of compound 2j in comparision with donepezil on AChE. The other tested compounds showed weak or no inhibition against AChE as promising anticancer agents.

8 January 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RSRyosuke Shinouchi
Ryosuke Shinouchi
BTBengisu Turgutalp
Bengisu Turgutalp
RORohini Shivraj Ople
Rohini Shivraj Ople
SEShainnel Eans
Shainnel Eans
AWAshai Kristian Williams
Ashai Kristian Williams
Jay McLaughlinJay McLaughlin
Jay McLaughlin
Background/Objectives: Neuropathic pain remains a significant clinical challenge, with current treatments often providing inadequate relief and adverse effects. Sigma receptors (SRs) modulate nociception and have emerged as potential therapeutic targets for neuropathic pain. Although putative sigma-1 receptor (S1R) ligands have demonstrated analgesic efficacy in preclinical models, their in vivo efficacy and safety profiles require further clarification. Methods: Analogs of well-known selective S1R ligand UVM147 were synthesized using 3-component Ugi reactions and examined in vitro for receptor affinity in radioligand competition binding assays and in vivo with mouse models of neuropathic and inflammatory pain and adverse effects. Results: Three novel heterocyclic compounds (RO-4-3, RO-5-3, and RO-7-3) displayed in vitro nanomolar affinity with varying selectivity for both SR subtypes (S1R and S2R). When screened in vivo at a dose of 30 mg/kg s.c. in mice first subjected to chronic constriction injury (CCI), RO-5-3 and RO-7-3 possessed anti-allodynic potential, while UVM147 was inactive. Upon full characterization, RO-5-3 significantly attenuated mechanical allodynia in a dose-dependent manner, while RO-7-3 was ineffective at higher doses. Both compounds dose-dependently attenuated nociceptive behaviors in the mouse formalin assay. RO-5-3 induced mild respiratory depression without impairing locomotor activity, whereas RO-7-3 caused transient respiratory depression and locomotor impairment. Additionally, RO-5-3, but not RO-7-3, induced conditioned place aversion consistent with potential S2R involvement. Conclusions: RO-5-3 exerts antinociceptive and anti-allodynic effects with minimal adverse behavioral effects, supporting the role of SRs in pain modulation. These results add to growing evidence supporting the development of SR ligands as efficacious therapeutics for neuropathic pain with fewer clinical liabilities.